Into Orexigen, Yet Again
Research - Orexigen Therapeutics (OREX) has again dipped below $5.50, which we find attractive 6 weeks ahead of the September 11 PDUFA decision for NB32 (Contrave, naltrexone/bupropion), … Continue Reading
Read nowAuthor Archives: Jake King
AcelRx’s Zalviso Met with a CRL
Research - After the bell on Friday evening, AcelRx (ACRX) reported that the FDA has issued a Complete Response Letter (CRL) to the company’s new drug application for Zalviso (sufentanil … Continue Reading
Read now
Incyte Says Phase 3 Failure Doesn’t Matter for Approval in Rare Blood Disorder
Insights - A second late-stage study of Incyte’s (INCY) Jakafi (ruxolitinib) in polycythemia vera (PV) failed on Wednesday, though the company says the study isn’t necessary for FDA approval. RELIEF was … Continue Reading
Read now
First up in BioPharma Earnings, Biogen Idec Tops Estimates
Insights - Biogen Idec (BIIB) trounced analyst estimates on Wednesday, a beat led by $700 million in Tecfidera sales during the quarter that topped consensus estimates for $561 million. Ex-U.S., the … Continue Reading
Read now
Biotech Stocks are Under Scrutiny Once Again
Research - Investors are skittish again, and healthcare investors more than others. Here’s why. In the Fed’s semi-annual monetary policy report, which accompanied Chairwoman Janet Yellen’s testimony before … Continue Reading
Premium
There’s Reason to Believe Tekmira Can Overcome this Safety Issue
Insights - There may be reason for investors to get comfortable with Tekmira's (TKMR) latest safety issue. Here's why.
Read now
For This Small Bio, a Heap of Events in the Second Half
Research - This small biotech company has three trials reading out in the second half of this year. First up, a phase 3 pivotal sometime this quarter.
Premium